Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. (NUVL) filed a Form 4 disclosing routine director equity compensation. Director Michael L. Meyers reported transactions dated 18 June 2025.
- Restricted Stock Units (RSUs): 2,647 Class A shares awarded at no cost. RSUs vest in full on the earlier of 18 June 2026 or the company’s next annual shareholders’ meeting, contingent on continued service.
- Stock Options: 4,147 options granted with a US$75.53 exercise price and 18 June 2035 expiry. The entire option grant vests on the same schedule as the RSUs.
- Post-transaction ownership: Meyers now directly holds 5,146 Class A shares. All newly reported securities were granted, not purchased on the open market.
The filing reflects standard annual board compensation rather than an open-market purchase or sale. As such, the event is generally viewed as neutral to Nuvalent’s valuation, though the additional insider ownership modestly aligns director and shareholder interests.
Nuvalent, Inc. (NASDAQ: NUVL) – Form 4 filing dated 20 Jun 2025
Director Grant C. Bogle reported the receipt of two equity awards on 18 Jun 2025:
- 2,647 restricted stock units (RSUs) representing Class A common shares. The RSUs were awarded at no cash cost and will vest in full on the earlier of 18 Jun 2026 or the company’s next annual meeting, conditional on continued board service.
- 4,147 stock options with an exercise price of $75.53, also vesting on the same schedule and expiring on 18 Jun 2035.
Following the grant, Bogle’s direct beneficial ownership stands at 5,847 Class A shares and 4,147 vested/unvested options. The transaction was coded “A” (award) and involved no open-market purchase or sale of shares, indicating routine, board-approved compensation rather than an insider-driven valuation signal.
The share amounts involved are modest relative to Nuvalent’s public float; therefore, any dilution effect is immaterial. No changes to corporate strategy, earnings outlook, or insider sentiment beyond standard compensation practices are implied by this filing.
Nuvalent, Inc. (NUVL) filed a Form 4 disclosing that director Christy J. Oliger received new equity awards on 18 June 2025.
- 3,971 Restricted Stock Units (RSUs): Granted at no cost. The RSUs convert to an equal number of Class A shares in three equal annual installments beginning one year from the grant date, provided the director remains in service.
- 6,119 Stock Options: Right to buy Class A shares at an exercise price of $75.53, expiring 18 June 2035. Vesting occurs monthly over the three-year period following the grant.
Post-grant, Oliger directly owns 3,971 Class A shares and holds derivative rights (options) to acquire an additional 6,119 shares. The filing reports no sales or dispositions.
These awards form part of Nuvalent’s standard director compensation package, creating long-term alignment with shareholder interests through multi-year vesting schedules. Because the transactions are grants rather than market purchases or sales, they do not immediately affect cash flow or trading volume but do incrementally increase potential dilution if options are exercised in the future.
Form 3 Overview: Nuvalent, Inc. (NUVL) filed an Initial Statement of Beneficial Ownership for Ms. Christy J. Oliger on 06/20/2025, reporting an event date of 06/18/2025.
Key Details:
- Reporting Person: Christy J. Oliger
- Relationship to Issuer: Director (no other roles indicated)
- Beneficial Ownership: The filer explicitly states “No securities are beneficially owned.”
- Filing Type: Form filed by one reporting person; accompanied by a Power of Attorney (Exhibit 24) signed by attorney-in-fact Nathan N. McConarty.
Investor Takeaway: A Form 3 signals an insider’s entry into the company’s reporting framework. However, because the form shows zero shares owned, there is no immediate dilution, concentration change, or valuation signal. The filing is largely administrative, confirming Ms. Oliger’s board position and future reporting obligations under Section 16(a).
Nuvalent, Inc. (NASDAQ: NUVL) filed a Form 8-K covering two corporate-governance items dated June 18, 2025.
Board change (Item 5.02): The Board unanimously elected Christy J. Oliger as an independent Class III director, effective immediately. She will serve until the 2027 annual meeting and join the Audit Committee. Compensation aligns with the existing non-employee director policy and includes:
- Initial stock option for 6,119 shares at an exercise price of $75.53, vesting monthly over three years.
- Initial RSU award of 3,971 shares, vesting annually over three years.
- Annual cash retainers and ongoing equity grants as stipulated in the policy.
2025 Annual Meeting results (Item 5.07): Quorum was strong with 64.38 million votes representing 97.01 % of outstanding shares. Outcomes were:
- Director elections: Grant Bogle (99.87 % support); James R. Porter, Ph.D. (99.78 %); Anna Protopapas (86.27 %).
- Say-on-pay: Approved with 83.8 % (53.52 m for, 10.36 m against).
- Auditor ratification: KPMG LLP re-approved with 99.98 % support.
Investor take-away: The filing is largely procedural. The addition of an experienced independent director strengthens oversight, while voting results confirm broad shareholder support for existing leadership and compensation structure.